Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study

BACKGROUND: Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs at an early stage of disease, late stage, or is spre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Ton, Al Khleifat, Ahmad, Meurgey, Jacques-Henri, Jones, Ashley, Leigh, P Nigel, Bensimon, Gilbert, Al-Chalabi, Ammar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899963/
https://www.ncbi.nlm.nih.gov/pubmed/29525492
http://dx.doi.org/10.1016/S1474-4422(18)30054-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899963/
https://www.ncbi.nlm.nih.gov/pubmed/29525492
http://dx.doi.org/10.1016/S1474-4422(18)30054-1

Ejemplares similares